Abstract library

4 results for "Kobayashi".
#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas
Introduction: Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Ph.D. Susumu Hijioka
Authors: Hijioka S, Hosoda W, Matsuo K, Ueno M, ...
Keywords: NET G3, NEC, KRAS, Rb
#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Keywords: prop-up, japan, gep-nen
#2121 Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: M.D., Ph.D. Yasushi Ichikawa
#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD,PhD Yasunari Sakamoto
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, ...
Keywords: Streptozocin, pNETs